In 2012, most analysts/investors rated, in fact, still rate Affymetrix, Inc. (NASDAQ: AFFX) a sell mainly because of its poor share performance throughout the year. Truth be told, this stock has been pretty unstable since 2010, when it used to trade in the range of $10 per share. However, the tide seems to be turning for Affymetrix, given its improved earnings results as well as entry into the Korean genomic market. The entry into the Korean genomic market is the latest from the company, having entered into partnership with DNA Link, Inc. (127120: KS), a Korean genomics-based biotechnology company......